1,869
Views
0
CrossRef citations to date
0
Altmetric
Commentary

Bibliometric analysis of hyperpolarization-activated cyclic nucleotide-gated (HCN)channels research (2004-2020)

, ORCID Icon, , , &
Pages 49-59 | Received 14 Oct 2021, Accepted 16 Nov 2021, Published online: 02 Mar 2022

References

  • Biel M, Wahl-Schott C, Michalakis S, et al. Hyperpolarization-activated cation channels: from genes to function. Physiol Rev. 2009 Jul;89(3):847–885.
  • Han Y, Lyman KA, Foote KM, et al. The structure and function of TRIP8b, an auxiliary subunit of hyperpolarization-activated cyclic-nucleotide gated channels. Channels (Austin). 2020 Dec;14(1):110–122.
  • Sartiani L, Mannaioni G, Masi A, et al. The hyperpolarization-activated cyclic nucleotide-gated channels: from biophysics to pharmacology of a unique family of ion channels. Pharmacol Rev. 2017 Oct;69(4):354–395.
  • Khangura RK, Sharma J, Bali A, et al. An integrated review on new targets in the treatment of neuropathic pain. Korean J Physiol Pharmacol. 2019 Jan;23(1):1–20.
  • Han Y, Lyman KA, and Foote KMet al, The structure and function of TRIP8b, an auxiliary subunit of hyperpolarization-activated cyclic-nucleotide gated channels. Channels (Austin). 2020 Dec;14(1):110–122. doi: 10.1080/19336950.2020.1740501. PMID: 32189562; PMCID: PMC7153792.
  • Arimitsu T, Nuriya M, Ikeda K, et al. Activity-dependent regulation of HCN1 protein in cortical neurons. Biochem Biophys Res Commun. 2009 Sep 11;387(1):87–91.
  • Refisch A, Chung HY, Komatsuzaki S, et al. A common variation in HCN1 is associated with heart rate variability in schizophrenia. Schizophr Res. 2021 Mar;229:73–79.
  • Liu X, Ji Q, Liu F, et al. HCN2 contributes to oxaliplatin-induced neuropathic pain by inducing spinal long-term potentiation via activation of NMDA receptor-mediated CaMKII signaling. Brain Res Bull. 2020 Jun;159:61–66.
  • Huang H, Zhang Z, Huang D. Decreased HCN2 channel expression attenuates neuropathic pain by inhibiting pro-inflammatory reactions and NF-κB activation in mice. Int J Clin Exp Pathol. 2019 Jan 1;12(1):154–163.
  • Stieber J, Stöckl G, Herrmann S, et al. Functional expression of the human HCN3 channel. J Biol Chem. 2005 Oct 14;280(41):34635–34643.
  • Ying SW, Tibbs GR, Picollo A, et al. PIP2-mediated HCN3 channel gating is crucial for rhythmic burst firing in thalamic intergeniculate leaflet neurons. J Neurosci. 2011 Jul 13;31(28):10412–10423.
  • Kelmendi B, Holsbach-Beltrame M, McIntosh AM, et al. Association of polymorphisms in HCN4 with mood disorders and obsessive compulsive disorder. Neurosci Lett. 2011 Jun 8;496(3):195–199.
  • Tae HS, Smith KM, Phillips AM, et al. Gabapentin modulates HCN4 channel voltage-dependence. Front Pharmacol. 2017;8:554.
  • Ueda K, Hirano Y, Higashiuesato Y, et al. Role of HCN4 channel in preventing ventricular arrhythmia. J Hum Genet. 2009 Feb;54(2):115–121.
  • Zobeiri M, Chaudhary R, Blaich A, et al. The hyperpolarization-activated HCN4 channel is important for proper maintenance of oscillatory activity in the thalamocortical system. Cereb Cortex. 2019 May 1;29(5):2291–2304.
  • Gao Y, Shi S, Ma W, et al. Bibliometric analysis of global research on PD-1 and PD-L1 in the field of cancer. Int Immunopharmacol. 2019 Jul;72:374–384.
  • Zhao D, Li J, Seehus C, et al. Bibliometric analysis of recent sodium channel research. Channels. 2018;12(1):311–325.
  • Lyman KA, Han Y, Chetkovich DM. Animal models suggest the TRIP8b-HCN interaction is a therapeutic target for major depressive disorder. Expert Opin Ther Targets. 2017 Mar;21(3):235–237.
  • Lewis AS, Estep CM, Chetkovich DM. The fast and slow ups and downs of HCN channel regulation. Channels (Austin). 2010 May-Jun;4(3):215–231.
  • Lewis AS, Chetkovich DM. HCN channels in behavior and neurological disease: too hyper or not active enough? Mol Cell Neurosci. 2011 Feb;46(2):357–367.
  • Dai GC, Zagotta WN. Structural determinants of the hyperpolarization-dependent gating of HCN channels. Biophys J. 2020;118(3):331A–332A.
  • Dai G, Aman TK, DiMaio F, et al. Electromechanical coupling mechanism for activation and inactivation of an HCN channel. Nat Commun. 2021 May 14;12(1):2802.
  • Robinson RB, Siegelbaum SA. Hyperpolarization-activated cation currents: from molecules to physiological function. Annu Rev Physiol. 2003;65(1):453–480.
  • Pape HC. Queer current and pacemaker: the hyperpolarization-activated cation current in neurons. Annu Rev Physiol. 1996;58(1):299–327.
  • Ludwig A, Zong X, Jeglitsch M, et al. A family of hyperpolarization-activated mammalian cation channels. Nature. 1998 Jun 11;393(6685):587–591.
  • Wainger BJ, DeGennaro M, Santoro B, et al. Molecular mechanism of cAMP modulation of HCN pacemaker channels. Nature. 2001 Jun 14;411(6839):805–810.
  • Magee JC. Dendritic hyperpolarization-activated currents modify the integrative properties of hippocampal CA1 pyramidal neurons. J Neurosci. 1998 Oct 1;18(19):7613–7624.
  • Santoro B, Liu DT, Yao H, et al. Identification of a gene encoding a hyperpolarization-activated pacemaker channel of brain. Cell. 1998 May 29;93(5):717–729.
  • Notomi T, Shigemoto R. Immunohistochemical localization of Ih channel subunits, HCN1-4, in the rat brain. J Comp Neurol. 2004 Apr 5;471(3):241–276.
  • Iacone Y, Morais TP, David F, et al. Systemic administration of ivabradine, a hyperpolarization-activated cyclic nucleotide-gated channel inhibitor, blocks spontaneous absence seizures. Epilepsia. 2021;62(7):1729–1743.
  • Zhu X, Zhou Y, and Yuan Get al, Bibliometric analysis of nicotinic acetylcholine receptors channel research (2000-2020). Channels (Austin). 2021 Dec;15(1):298–309. doi: 10.1080/19336950.2021.1882113. PMID: 33615989; PMCID: PMC7901545.
  • Rivolta I, Binda A, Masi A, and DiFrancesco JC. Cardiac and neuronal HCN channelopathies. Pflugers Arch. 2020 Jul;472(7):931–951. doi: 10.1007/s00424-020-02384-3. Epub 2020 May 18. PMID: 32424620.
  • Lainez S, Tsantoulas C, and Biel Met al, HCN3 ion channels: roles in sensory neuronal excitability and pain. J Physiol. 2019 Sep;597(17):4661–4675. doi: 10.1113/JP278211. Epub 2019 Jul 27. PMID: 31290157.
  • Ramentol R, Perez ME, and Larsson HP. Gating mechanism of hyperpolarization-activated HCN pacemaker channels. Nat Commun. 2020 Mar 17;11(1):1419. doi: 10.1038/s41467-020-15233-9. PMID: 32184399; PMCID: PMC7078272.
  • Nickel FT, Seifert F, and Lanz Set al, Mechanisms of neuropathic pain. Eur Neuropsychopharmacol. 2012 Feb;22(2):81–91. doi: 10.1016/j.euroneuro.2011.05.005. Epub 2011 Jun 14. PMID: 21672666.
  • Melgari D, Ng GA, and Hancox , JC, by Melgari et al Article, Letter by Melgari et al Regarding Article, ”Ivabradine: Role in the Chronic Heart Failure Armamentarium”. Circulation. 2016 Sep 27;134(13):e296–7. doi: 10.1161/CIRCULATIONAHA.116.023752. PMID: 27672201.
  • Novella Romanelli M, Sartiani L, and Masi Aet al, HCN Channels Modulators: The Need for Selectivity. Curr Top Med Chem. 2016;16(16):1764–91. doi: 10.2174/1568026616999160315130832. PMID: 26975509; PMCID: PMC5374843.
  • Cao Y, Pang J, and Zhou P. HCN Channel as Therapeutic Targets for Heart Failure and Pain. Curr Top Med Chem. 2016;16(16):1855–61. doi: 10.2174/1568026616666151215104058. PMID: 26667117.
  • Iacone Y, Morais TP, and David Fet al, Systemic administration of ivabradine, a hyperpolarization-activated cyclic nucleotide-gated channel inhibitor, blocks spontaneous absence seizures. Epilepsia.